Supplemental material
Expert Review of Vaccines
Volume 23, 2024 - Issue 1
Original Research
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
Shigeki Nakamuraa Department of Microbiology, Tokyo Medical University, Tokyo, Japan
https://orcid.org/0000-0001-5272-8886View further author information
https://orcid.org/0000-0001-5272-8886View further author information, Masashi Mikamib Health and Value, Pfizer Japan Inc., Tokyo, Japanhttps://orcid.org/0000-0001-7731-847XView further author information
https://orcid.org/0000-0001-7731-847XView further author information, Tomoyuki Hayamizuc Vaccine Medical Affairs, Medical Japan, Pfizer Japan Inc., Tokyo, Japanhttps://orcid.org/0009-0002-2989-4303View further author information
https://orcid.org/0009-0002-2989-4303View further author information, Naohiro Yonemotob Health and Value, Pfizer Japan Inc., Tokyo, Japanhttps://orcid.org/0000-0003-3637-2095View further author information
https://orcid.org/0000-0003-3637-2095View further author information, , Mark Gouldsone Health Economics and Outcomes Research, Putnam, Westport, Irelandhttps://orcid.org/0009-0006-7259-0881View further author information
https://orcid.org/0009-0006-7259-0881View further author information, , Jeffrey Vietrif Global Access and Value, Pfizer Inc., Collegeville, PA, USAhttps://orcid.org/0000-0002-5610-3098View further author information
https://orcid.org/0000-0002-5610-3098View further author information & Kazumasa Kameib Health and Value, Pfizer Japan Inc., Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-7220-5142View further author information
https://orcid.org/0000-0001-7220-5142View further author information show all